Article
Pseudoirreversible inhibition elicits persistent efficacy of a sphigosine-1-phosphate…
medRxiv · 2024 · Maruyama, Y.; Ohsawa, Y.; Suzuki, T.; Yamauchi, Y.; Ohno, K.; Inoue, H.; Yamamoto, A.; Hayashi, M.; Okuhara, Y.; Muramatsu, W.; Namiki, K.; Miyauchi, M.; Miyao, T.; Hagiwara, N.; Ishikawa, T.; Horie, K.; Hayama, M.; Akiyama, N.; Hirokawa, T.; Akiyama, T.
Key facts
| Title | Pseudoirreversible inhibition elicits persistent efficacy of a sphigosine-1-phosphate receptor-1 antagonist |
|---|---|
| First author | Maruyama, Y.; Ohsawa, Y.; Suzuki, T.; Yamauchi, Y.; Ohno, K.; Inoue, H.; Yamamoto, A.; Hayashi, M.; Okuhara, Y.; Muramatsu, W.; Namiki, K.; Miyauchi, M.; Miyao, T.; Hagiwara, N.; Ishikawa, T.; Horie, K.; Hayama, M.; Akiyama, N.; Hirokawa, T.; Akiyama, T. |
| Journal | medRxiv |
| Published | Apr 8, 2024 |
| DOI | 10.1101/2023.05.08.539826 |
| Devices mentioned | K171765, K843077, K843710 |
| Product codes mentioned | JJH, LXG, MVU |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1